It needs to work within the constraints imposed by these three issues. Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (DNA 0.70%) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. Delivering on those plans would make it a smart stock to own as well. But for now, it's still trying to find its footing, and it's a riskier bet than investors may realize. So without further ado, here ...